A novel GJA8 mutation in an Iranian family with progressive autosomal dominant congenital nuclear cataract

C E Willoughby, Sara Arab, R Gandhi, S Zeinali, Seddigheh Arab, D Luk, G Billingsley, F L Munier, E Heon

Cataract results from a loss in transparency of the crystalline lens. Worldwide, there are an estimated 20 million people blind (Snellen visual acuity of 3/60 or less) as a result of cataract.1 Despite effective surgical treatment, demand outstrips supply in both Western and developing countries, for many reasons,2,3 and other disease modifying strategies must be considered. A strong genetic predisposition to the development of congenital cataract and age related cataract has been well documented.45 Inherited predisposition to the development of congenital cataract and age related cataract accounts for at least 50% of all congenital cataracts,6 and shows marked inter- and intrafamilial variation.7 Twin studies on age related cataracts in the United Kingdom estimate that two thirds of cortical cataract and at least half of nuclear cataracts can be explained by genetic factors.8,9

Previous genetic studies of congenital cataracts identified connexin 50 (Cx50) as a cataract related gene.10–12 Here we report a novel heterozygous R23T mutation in the GJA8 gene (MIM#600897) encoding connexin 50, in an Iranian family affected by a progressive autosomal dominant congenital nuclear cataract. In addition, to determine the genetic contribution of connexin 50 mutations to the basis of congenital and age related cataracts for our mutation (R23T) and the other three published Cx50 mutations (P88S, E48K, and I247M),10–12 two additional patient populations were screened for those changes.

METHODS

Observing the principles of the Declaration of Helsinki, a four generation Iranian family with autosomal dominant congenital cataract was recruited for molecular analysis (fig 1A). Twenty seven family members (12 affected and 15 unaffected) participated and had a full ocular assessment to document the phenotype. The phenotype was characterised by autosomal dominant, bilateral, congenital nuclear cataracts that progressed to cause visual impairment by the second decade. No other systemic findings or ocular defects were present, including microcornea or microphthalmia. All participants required cataract surgery and intraocular lens implantation in the second and third decades because of dense nuclear (fetal/embryonal) cataract. There was no evidence of nystagmus, and reasonably good visual function was obtained postoperatively (range of Snellen visual acuity 6/9.5 to 6/12). This suggests that visual deprivation was minimal in the critical period of visual development.

With informed consent, genomic DNA was extracted from peripheral blood leucocytes using standard protocols. The affected status (presence of cataracts) was determined before genetic analysis. A panel of cataract candidate loci was selected for preliminary haplotype analysis. Polymerase chain reaction (PCR) based genotyping of microsatellite markers was done on a Pharmacia automated sequencer. The marker order (cenotermic to telomeric) and the intermarker distances (centiMorgans (cM)) were obtained from the Marshfield Genetic Database (www.marshfield.org/genetics/maps). The position of genes in relation to markers was determined using the UCSC Human Genome Browser (http://genome.ucsc.edu). Haplotype analysis of the genotypes from markers of a 9 cM region on chromosome 1 (D1S2669-1.11cM - D1S514 - 8.60cM - D1S1595) suggested putative linkage (fig 1A). Linkage analysis using the MLINK program of the LINKAGE package v5.2 gave a maximum two point LOD score (Z Max) of 2.62 for marker D1S514 (Z = 0.05) (table 1). This region contained a strong candidate, the GJA8 gene encoding connexin 50 (Cx50), as Cx50 mutations cause cataracts in humans and mice.10–12 Connexin 50 consists of two exons, of which only one is coding (exon 2). The coding of Cx50 (GJA8) was sequenced using published protocols.10 11 17 Primers were modified from those published earlier18 or designed from the genomic sequence (http://www.ncbi.nlm.nih.gov/GenBank/for genomic contig NT_034400.2; gi:27478327), to amplify two overlapping

Key points

- The molecular characterisation of an Iranian family with an autosomal dominant progressive congenital nuclear cataract is described. Affected members were found to have a novel heterozygous missense mutation R23T in the GJA8 gene encoding connexin 50 (Cx50). This sequence change segregated with the disease phenotype in the family and was not found in 152 control individuals, including 52 ethnically matched controls.
- This non-conservative mutation replaces an evolutionarily conserved basic polar charged amino acid by an uncharged polar amino acid at position 23 in the amino-terminus of Cx50. The R32T mutation may result in failure to form normal gap junctions (loss of function mutation) or alter the function of endogenous wild-type connexins (dominant negative mutation).
- In this family, there was a novel progressive phenotype, mimicking an early onset age related nuclear cataract. Three heterozygous missense Cx50 mutations (P88S, E48K, and I247M) have previously been described in three geographically distinct families with zonular pulverulent or zonular nuclear congenital cataracts. The mutational screening of a population of patients with congenital cataracts (n = 37) and another with age related cataract (n = 44) failed to show any contribution of the four known Cx50 mutations.
amplicons of exon 2 of Cx50: amplicon 1 (847 base pairs (bp)) F5
\[9\] -cactacttcctgtacgggttc-3
\[9\] -ctcttgccctacg-taagcttgg-3
\[9\] and R5
\[9\] -cccgcgttagcaaaaaca-gat-3
\[9\] -cacagaggccacagacaacat-3.
Bidirectional sequencing detected the transition 68G
\[R\] C resulting in the substitution of an arginine residue (A
\[G\] A) to threonine (A
\[C\] A) in codon 23 (R23T) (fig 1C).

RESULTS

The presence of the mutation was confirmed by the loss of a restriction site for the enzyme HinfI, producing an undigested fragment of 706 base pairs (bp) compared with the control fragments of 574 bp and 132 bp (band not shown) and a common 27 bp fragment (not shown). (C) Sequence chromatograms showing the mutation detected in family with a heterozygous 68G → C transition that converts an arginine residue (AGA) to threonine (ACA). (D) Sequence alignment (Clustal X38; ftp://ftp.genome.u-strasbg.fr/pub/ClustalX/) of Cx50 with other connexin proteins. Identical residues are highlighted with a dark background. The asterisk indicates the position of the R23T mutation where an arginine (R) or lysine (K) (basic polar group) is highly conserved throughout all connexins.

Table 1

<table>
<thead>
<tr>
<th>Marker</th>
<th>LOD score at recombination fraction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>D1S2669</td>
<td>-1.22</td>
</tr>
<tr>
<td>D1S514</td>
<td>0.26</td>
</tr>
<tr>
<td>D1S595</td>
<td>-7.99</td>
</tr>
</tbody>
</table>
screened two groups for these mutations by restriction endonuclease analysis (table 2). The first group consisted of 37 Swiss patients with congenital and juvenile cataracts, and the second of 44 Swiss patients with age related nuclear sclerotic cataracts. The four known Cx50 mutations were not detected in this study population.

**DISCUSSION**

Connexins are a large family of transmembrane proteins that form gap junctions. All connexons have four transmembrane domains and two extracellular loops with cytoplasmic N and C termini (fig 2). A single gap junction is formed from two connexon hemichannels, from adjacent cells, which are constructed from hexameric oligomerisation of protein subunits or connexons. The 68G→C change results in an arginine (R) to threonine (T) amino acid substitution within the cytoplasmic N terminus region at the membrane–cytoplasm boundary of the first transmembrane domain (M1: amino acids 24–45; fig 2). This non-conservative mutation (R23T) replaces a basic polar charged amino acid by an uncharged polar amino acid at position 23 in the amino terminus. Positively charged amino acid residues in the hydrophilic cytoplasmic domains of membrane proteins are important factors in the membrane insertion and orientation of hydrophobic transmembrane elements. An arginine (R) or lysine (K) residue, both basic polar charged amino acids, are evolutionarily conserved residues across species for connexin 50 and other Cx molecules at that position (fig 1D). Substitutions in the amino acid residues of the N terminus may interfere with the conformation and flexibility of the amino terminus, and also with voltage gating. In addition, the mutation may have a dominant negative effect owing to a direct interaction of the intact and defective connexins at the plasma membrane level. Mutations in the N terminus of other connexins have been documented in Charcot-Marie-Tooth peripheral neuropathy (Cx32), autosomal recessive (DFNB1) and dominant (DFNA3) human deafness (Cx26) (http://www.crg.es/deafness/intro.htm), erythrokeratodermia variabilis (Cx31), Clouston syndrome (Cx30), and keratitis-ichthyosis-deafness (KID) syndrome (Cx26).

Three previously published heterozygous missense Cx50 mutations (P88S, E48K, and I247M) have been described causing autosomal dominant congenital cataracts with either a zonular or zonular nuclear pulverulent cataract (CZP1; MIM#116200). The P88S mutation is located in the second transmembrane domain (M2), the E48K in the first extracellular domain (E1), and the I247M in the cytoplasmic C terminus (fig 2). These mutations arose in three distinct ethnic populations—British, Pakistani, and Russian. Cataract progression was not reported in the P88S mutation but cataract was present at birth or developed in infancy, and all affected individuals had surgery at an unspecified time. The E48K mutation resulted in a non-progressive cataract that was present at birth or in early infancy and the I247M associated cataract began at three years of age in one individual with progression, but did not require cataract surgery; the level of visual impairment was not reported. The novel R23T mutation described here, unlike the previous Cx50 mutations, caused a progressive nuclear cataract that was present at birth and resulted in significant visual impairment in the second and third decades requiring cataract extraction.

Three connexins are expressed in the lens: connexin 43 (Cx43), connexin 46 (Cx46), and Cx50. Cx43 is expressed mainly in the lens epithelial cells, while Cx46 and Cx50 are expressed in lens fibre cells. The lens is an avascular structure and lens fibres lose all intracellular organelles during development. The lens has developed an extensive cell–cell communication system using connexins to maintain its transparency. Gap junction intercellular communication is an essential part of this system, which facilitates the exchange of ions, metabolites, signalling molecules, and other molecules with a molecular weight up to 1 kDa. Defects in Cx50 and Cx46 cause human and murine cataracts, but the specific roles of these two connexins in the lens are not fully understood. Both Cx50 and Cx46 localise to the same gap junction plaque in the plasma membrane of lens fibre cells, and the size of these plaques in cortical fibres is dependent on the presence of Cx50.

A naturally occurring Cx50 autosomal semidominant mutation (G22R) results in cataracts in the lens opacity 10 (Lop 10) mouse. This amino acid substitution, which is neighbour to our mutant residue (R23T), results failure to form normal gap junctions (loss-of-function mutation) and alters the function of endogenous wild type Cx46 (dominant negative

**Table 2**  
Polymerase chain reaction primers and restriction digest fragment sizes used to screen the congenital and age related cataract populations for the four known Cx50 mutations.

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Restriction site</th>
<th>Primers (sense/antisense)</th>
<th>Wild type (bp)</th>
<th>Mutant (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R23T</td>
<td>Loss of HNF1</td>
<td>F5→ccctgcgtaccaaaacagat-3' and R5→ccctgcgtaccaaaacagat-3'</td>
<td>574, 132, 27</td>
<td>706, 27</td>
</tr>
<tr>
<td>P88S</td>
<td>Creates MnlI</td>
<td>F5→ctggggtgctgatcac-3' and R5→ccctgcgtaccaaaacagat-3'</td>
<td>81</td>
<td>50, 31</td>
</tr>
<tr>
<td>E48K</td>
<td>Loss of FokI</td>
<td>F5→ccctgcgtaccaaaacagat-3' and R5→ccctgcgtaccaaaacagat-3'</td>
<td>193, 172, 33</td>
<td>193, 205</td>
</tr>
<tr>
<td>I247M</td>
<td>Loss of HNF1</td>
<td>F5→ctggggtgctgatcac-3' and R5→ccctgcgtaccaaaacagat-3'</td>
<td>610, 237</td>
<td>847</td>
</tr>
</tbody>
</table>

**Figure 2**  
Schematic diagram of the predicted Cx50 polypeptide and location of known mutations. M1→M4, transmembrane domains 1→4; E1 and E2, extracellular domains 1 and 2, respectively. [HMM Top Prediction of Transmembrane Helices and Protein Topology server](http://www.enzim.hu/hmmtop/).
mutation). Heterozygous mice, which are homologous to our family, have a variable expression of cataracts, ranging from no lens opacity to snowflake opacities (pulverulent) and to full expression with dense fetal nuclear opacities. A second dominant mouse cataract mutant, No2, is caused by a different point mutation in Cx50, resulting in the substitution of aspartic acid with alanine at codon 47 (D47A). No histological or biochemical data were reported for the No2 mutant, but in vitro studies in Xenopus oocytes suggested the D47A mutation acts as a loss-of-function mutation. What is clear from these human and murine studies is that different mutations in Cx50 can lead to distinctive cataract morphology. Evidence from the Lop10 mutant suggests further complexity to cataractogenesis, with mutant Cx50 interacting with Cx46 and potentially with other lens proteins or intercellular communications. Whether or not these other cataract genes can act as modifiers of Cx50 has not been explored.

Conclusions
A novel heterozygous R23T mutation in the GJA5 gene encoding connexin 50 was identified in an Iranian family, causing a progressive autosomal dominant congenital nuclear cataract. Although this mutation is not common it further expands the genetic and phenotypic heterogeneity of cataract. The human connexin mutations identified to date do not appear to be a common cause of congenital or late onset cataract but they highlight the complexity of the clinical changes associated with connexin changes.

ACKNOWLEDGEMENTS
This work was supported by the Canadian Institutes of Health Research No CIHR49282 (EH), the Canadian Genetic Diseases Network (DL, EH), the Swiss National Science Foundation No 32-065230 (FLM), and the BUPA Foundation, Royal College of Ophthalmologists and the Research Training Centre, The Hospital for Sick Children, Toronto (CEW).

Authors’ affiliations
R Gandhi, G Billingsley, D Luk, Vision Science Research Program, Toronto Western Hospital, Toronto, Canada
C E Willoughby*, E Heon, Department of Ophthalmology, The Hospital for Sick Children, University of Toronto, Toronto, Canada
Sara Arab*, Department of Cardiology, Heart and Stroke, Richard Lewallen S, Berry V, Bhattacharya SS, et al. Mutation in the connexin 50 gene (GJA5) in an Iranian family, causing a progressive autosomal dominant congenital nuclear cataract.

REFERENCES

A novel GJA8 mutation in an Iranian family with progressive autosomal dominant congenital nuclear cataract

C E Willoughby, Sara Arab, R Gandhi, S Zeinali, Seddigheh Arab, D Luk, G Billingsley, F L Munier and E Héon

J Med Genet 2003 40: e124
doi: 10.1136/jmg.40.11.e124

Updated information and services can be found at:
http://jmg.bmj.com/content/40/11/e124

These include:

References
This article cites 35 articles, 16 of which you can access for free at:
http://jmg.bmj.com/content/40/11/e124#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Eye Diseases (298)
Genetic screening / counselling (886)
Epidemiology (630)
Visual development (7)
JMG Online mutation reports (168)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/